论文部分内容阅读
目的:对比研究在小儿咳嗽变异性哮喘的治疗中应用孟鲁司特钠与富马酸酮替酚片的实际价值,为临床治疗提供借鉴和参考。方法:选取中山市坦背医院2014年8月至2016年2月收治的60例小儿咳嗽变异性哮喘患儿,结合临床随机表法将其平均地列入观察组与对照组,观察组与对照组分别使用孟鲁司特钠与富马酸酮替芬进行治疗,对比两组治疗有效率、症状缓解时间以及不良反应的发生率。结果:观察组咳嗽缓解时间是(3.9±1.4)d,住院时间是(5.2±2.3)d,对照组咳嗽缓解时间是(5.7±1.3)d,住院时间是(7.4±2.5)d,差异均有统计学意义(P<0.05);观察组的治疗有效率是93.4%,不良反应的发生率是6.6%,对照组的治疗有效率是73.3%,不良反应的发生率是26.7%,差异均有统计学意义(P<0.05)。结论:在小儿咳嗽变异性哮喘的治疗中,与富马酸酮替酚片比较,孟鲁司特钠的疗效更佳,能够有效地改善患儿的症状,提高治疗有效率,缩短其治疗时间,且安全性强。
Objective: To compare the practical value of applying montelukast sodium and ketotifen fumarate tablets in the treatment of pediatric cough variant asthma, and provide references for clinical treatment. Methods: Sixty infants with pediatric cough variant asthma admitted from August 2014 to February 2016 in Tanshan Hospital of Zhongshan City were enrolled in the study group and the control group randomly. The patients in the observation group and the control group The patients were treated with montelukast sodium and ketotifen fumarate, respectively. The treatment efficiency, symptom relief time and the incidence of adverse reactions were compared between the two groups. Results: The cough relief time was (3.9 ± 1.4) days in the observation group and (5.2 ± 2.3) days in the observation group, and (5.7 ± 1.3) days in the control group and (7.4 ± 2.5) days in the control group (P <0.05). The effective rate of treatment was 93.4% in the observation group, 6.6% in the adverse reaction group, 73.3% in the control group, and 26.7% in the control group There was statistical significance (P <0.05). CONCLUSION: Montelukast sodium is more effective than ketotifen fumarate in the treatment of pediatric cough variant asthma, which can effectively improve the symptoms of children, improve the treatment efficiency and shorten the treatment time , And strong security.